Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORTITUDE-102: bemarituzumab plus mFOLFOX6 and nivolumab versus placebo plus mFOLFOX6 and nivolumab in FGFR2b-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma
MOH_2022-05-16_010782Phase 3Completed
- Sponsor
- Amgen
- Start
- May 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing Bemarituzumab + mFOLFOX6 + nivolumab with Placebo + mFOLFOX6 + nivolumab (2 arms). Primary endpoint: Overall survival. Started May 2022; status: completed.
02
Drugs
bemarituzumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on MOH_2022-05-16_010782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-05-16_010782.